Flavonoids and stilbenoids as a promising arsenal for the management of chronic arsenic toxicity.


Journal

Environmental toxicology and pharmacology
ISSN: 1872-7077
Titre abrégé: Environ Toxicol Pharmacol
Pays: Netherlands
ID NLM: 9612020

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 26 05 2022
revised: 29 08 2022
accepted: 01 09 2022
pubmed: 7 9 2022
medline: 5 10 2022
entrez: 6 9 2022
Statut: ppublish

Résumé

Rapid industrial and technological development has impacted ecosystem homeostasis strongly. Arsenic is one of the most detrimental environmental toxins and its management with chelating agents remains a matter of concern due to associated adverse effects. Thus, safer and more effective alternative therapy is required to manage arsenic toxicity. Based on existing evidence, native and indigenous plant-based active biomolecules appear as a promising strategy to mitigate arsenic-induced toxicity with an acceptable safety profile. In this regard, various phytochemicals (flavonoids and stilbenoids) are considered important classes of polyphenolic compounds with antioxidant and chelation effects, which may facilitate the removal of arsenic from the body more effectively and safely with regard to conventional approaches. This review presents an overview of conventional chelating agents and the potential role of flavonoids and stilbenoids in ameliorating arsenic toxicity. This report may provide a roadmap for identifying novel prophylactic/therapeutic strategies for managing arsenic toxicity.

Identifiants

pubmed: 36067934
pii: S1382-6689(22)00163-6
doi: 10.1016/j.etap.2022.103970
pii:
doi:

Substances chimiques

Antioxidants 0
Chelating Agents 0
Flavonoids 0
Phytochemicals 0
Stilbenes 0
Arsenic N712M78A8G

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

103970

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Awanish Mishra (A)

Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER) - Guwahati, Changsari, Kamrup, Assam 781101, India. Electronic address: awanish@niperguwahati.in.

Petro Oliinyk (P)

Danylo Halytsky Lviv National Medical University, Lviv, Ukraine. Electronic address: petrolinik1@gmail.com.

Roman Lysiuk (R)

Danylo Halytsky Lviv National Medical University, Lviv, Ukraine. Electronic address: pharmacognosy.org.ua@ukr.net.

Larysa Lenchyk (L)

National University of Pharmacy, Kharkiv, Ukraine. Electronic address: larysa.lenchyk@gmail.com.

Suraj Singh S Rathod (SSS)

School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, India. Electronic address: surajsinghrathod05@gmail.com.

Halyna Antonyak (H)

Ivan Franko National University of Lviv, Lviv, Ukraine. Electronic address: halyna.antonyak@gmail.com.

Roman Darmohray (R)

Danylo Halytsky Lviv National Medical University, Lviv, Ukraine. Electronic address: lvivdar@gmail.com.

Natalia Dub (N)

Andrei Krupynskyi Lviv Medical Academy, Lviv, Ukraine. Electronic address: oak_an@ukr.net.

Olha Antoniv (O)

Danylo Halytsky Lviv National Medical University, Lviv, Ukraine. Electronic address: olga.antoniv@ukr.net.

Oksana Tsal (O)

Danylo Halytsky Lviv National Medical University, Lviv, Ukraine. Electronic address: tsaloks@gmail.com.

Taras Upyr (T)

National University of Pharmacy, Kharkiv, Ukraine. Electronic address: upyrtaras@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH